Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-In-Pentetreotide
Chung G, Murren J, Rimm D. Quantitative in Situ Assessment of the Somatostatin Receptor in Breast Cancer to Assess Response to Targeted Therapy with 111-In-Pentetreotide. 2005 DOI: 10.21236/ada436873.Peer-Reviewed Original ResearchBreast cancerTissue microarraySSTR2 expressionClinical trialsPredominant receptor subtypeRadiolabelled SST analoguesMetastatic breast cancerRadiolabelled somatostatin analoguesMalignant breast epitheliumResponse/survivalBenign breast tissueCell lines expressionProgression of cancerSST analogsSomatostatin analoguesTargeted therapyReceptor subtypesSomatostatin receptorsBreast epitheliumCo-localization techniquesCancerBreast tissueSSTR2Protein expressionPeptide hormones